Zhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF

Stock News

2025/12/08

Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.

Under the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.

In June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1180947982"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180947982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180947982?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180947982","market":"sh","top_or_hot":-1,"title":"Zhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF","media":"Stock News","content":"<p>Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.</p>\n<p>Under the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.</p>\n<p>In June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology-B (06622) to Collaborate with Tansheng Pharma in Taiwan for Clinical Introduction and Future Commercialization of BRIMOCHOL™ PF\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 16:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.</p>\n<p>Under the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.</p>\n<p>In June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"","article_id":"1180947982","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180947982","pubTimestamp":1765184087,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","BK1191":"制药","BK1574":"生物医药B类股","BK1587":"次新股","06622":"兆科眼科-B","BK1583":"高瓴概念"},"translate_title":"兆科眼科-B(06622)将与台湾丹生制药合作开展BRIMOCHOL的临床引进及未来商业化™PF","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"06622":1},"content_text":"Zhaoke Ophthalmology-B (06622) announced a strategic partnership with Taiwan-based Tansheng Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan. Tansheng Pharma specializes in chronic diseases and precision medicine, delivering safe and accessible healthcare solutions.\nUnder the agreement, Zhaoke grants Tansheng Pharma exclusive distribution rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan.\nIn June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}